The final report of the President's Commission on Combating Drug Addiction and the Opioid Crisis had one recommendation specifically directed to the US FDA, calling for it to establish guidelines for post-market surveillance related to diversion, addiction and other adverse consequences of controlled substances.
Trump's Opioid Commission Asks FDA To Boost Post-Market Vigilance
Pharma is criticized for aggressive marketing, but the report also seeks industry help in research on innovative medication.
More from Post-Marketing Regulation & Studies
More from Product Reviews
• By
All RSV vaccines with US FDA approval for high-risk younger adult patients will be incorporated in US CDC’s Advisory Committee for Immunization Practices recommendations. Merck’s infant RSV antibody is on track for a June vote
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
• By
Tracy Beth Høeg, who is reportedly re-examining Novavax’s COVID vaccine application, is the FDA rep at the CDC panel’s first meeting under the Trump Administration. She raised concerns about routine use of Jynneos for adolescents at risk of mpox and questioned how Moderna assessed efficacy of its COVID vaccines.